Advertisement

Topics

Bluebird Bio Presents More Data on its $1.8 Million Gene Therapy Zynteglo

20:00 EDT 13 Jun 2019 | BioSpace

Cambridge, Mass.-based bluebird bio released updated results from three clinical trials of its LentiGlobin gene therapy for transfusion-dependent Beta-thalassemia.

Original Article: Bluebird Bio Presents More Data on its $1.8 Million Gene Therapy Zynteglo

NEXT ARTICLE

More From BioPortfolio on "Bluebird Bio Presents More Data on its $1.8 Million Gene Therapy Zynteglo"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...